PubMed Health⌕ Search

Biomedical subjects

Naitee Ting

Publications and source records attributed to Naitee Ting.

2 recordsLinked to original sources

A modified large-sample approach to approximate interval estimation for a particular intraclass correlation coefficient.

We consider the problem of constructing a confidence interval for the intraclass correlation coefficient in an interrater reliability study when both raters and subjects are random effects in a two-way random effects model. A simulation study is conducted to investigate and compare the interval coverage per cents of three methods of approximation: (i) Satterthwaite's two moments, the standard approach; (ii) modified three moments, a newer approach; and (iii) modified large sample, the newest approach for this particular problem. One-sided lower and two-sided bounds are examined. For the two-moment approach, coverage of confidence intervals can be understated for not only one-sided bounds but also two-sided bounds. Coverage of confidence intervals for the modified large-sample approach is either correct or conservative and provides narrower two-sided widths than the modified three-moment approach, which can understate coverage on one-sided and two-sided bounds for two or three raters. The competing methods are illustrated with data from a reliability study of four raters evaluating the number of decayed, missing, and filled surfaces in the permanent teeth of ten subjects. Overall, the modified large-sample approach provides the most satisfactory performance of the three methods.

Clinical Trials as Topic↗

Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.

Bioequivalence studies are conducted to demonstrate equivalence in the bioavailability of the active ingredient in different formulations. The U.S. Food and Drug Administration (FDA) requires pharmaceutical companies to show bioequivalence between different formulations or generic companies to show bioequivalence between generic drugs and brand drugs before approval. A recent FDA guidance on bioequivalence proposes criteria for assessment of population bioequivalence (PBE) and individual bioequivalence (IBE) in a four-period cross-over design. In this paper, computer simulation is used to compare modified large sample (MLS) upper bounds with those proposed by the FDA to test for both PBE and IBE. The comparison criteria are the ability to maintain the stated test size and the simulated power of tests based on these bounds.

Computer Simulation↗